Advanced searches left 3/3

Carboplatin chemotherapy - Europe PMC

Summarized by Plex Scholar
Last Updated: 03 September 2022

* If you want to update the article please login/register

Ocular toxicity following carboplatin chemotherapy for neuroendocrine tumour of the bladder.

Introduction Carboplatin is a commonly used platinum analogue chemotherapeutic agent that is similar to cisplatin but is known to be more tolerable. The case study A 70-year-old man with a history of neuroendocrine bladder cancer underwent chemotherapy with carboplatin and etoposide. In his left eye, the patient had a similar episode 2 weeks after his third chemotherapy cycle. Discussion of carboplatin-induced ocular toxicology The current literature on carboplatin-induced ocular disease is scanty, but new cases have reported symptoms from 5 days to 2 weeks after carboplatin use.

Source link: https://europepmc.org/article/MED/36000302


Induction chemotherapy with paclitaxel, carboplatin and cetuximab for locoregionally advanced nasopharyngeal carcinoma: A single-center, retrospective study.

Background In locoregionally advanced nasopharyngeal cancer, the introduction of induction chemotherapy before chemoradiotherapy has improved survival over CRT alone. Methods We retrospectively reviewed 29 LA-NPC patients who received the combination of paclitaxel, carboplatin, and cetuximab as IC at the National Cancer Center Hospital East between March 2017 and April 2021. IC-PCE consisted of CBDCA area under the plasma concentration-time curve = 1. 5, PTX 80 mg/m 2, and Cmab, with an initial dose of 400 mg/m 2 followed by 250 mg/m 2 administered weekly for a maximum of eight weeks. After IC-PCE, 26 patients received concurrent cisplatin and radiotherapy, one received concurrent carboplatin/5-fluorouracil and radiotherapy, and two others received RT alone. During IC and 44. 8% during CRT, the incidence of adverse events of grade 3/4 was 34. 5%. IC-PCE is both safe and effective for LA-NPC, and it can be a treatment option for this disease.

Source link: https://europepmc.org/article/MED/36033502


The Effect and Mechanism of Curcumin Combined with Carboplatin Chemotherapy Promoting on Apoptosis of Lung Cancer HCC827 Cells.

After being treated by 1, 2, 5, 10, and 20 mg/mL carboplatin for 48 h, colorimetry revealed the inhibitory effects of 10 u03bc M, 50 bc M, 100 u03bc M, and 200 bc M CUR on GST activity in HCC827 cell spheres and HCC827 cell spheres. Conclusion The expression of stem cell marker CD133, SOX2, EpCAM, and drug resistance-related gene ABCG2 is elevated in HCC827 cell spheres, and HCC827 cell spheres retained the killing effect of different doses of CBP. By 10 u03bc M, 50 bc M, 100 u03bc M, and 200 u03bc M CUR, the growth of GST of HCC827 cell spheres was stymied. cell proliferation of HCC827 cell spheres was dramatically hampered, and cell apoptosis rate was elevated by 200 %bc M CUR mixed with 5 mg/mL CBP, rather than 200 bc M CUR alone. Adenovirus's upregulation of u03b2 -catenin by adenovirus partly reversed the results of CUR inhibition of the expression of u03b2 -catenin, SOX2, and ABCG2 in comparison to the empty vector adenovirus group's empty vector adenovirus group. Conclusion CUR inhibited cell proliferation and stem cell differentiation in HCC827 cell spheres and caused apoptosis by reduction of GST activity and u03b2 -catenin expression. CUR is expected to become a lung cancer and lung cancer stem cells treatment.

Source link: https://europepmc.org/article/MED/35979255

* Please keep in mind that all text is summarized by machine, we do not bear any responsibility, and you should always check original source before taking any actions

* Please keep in mind that all text is summarized by machine, we do not bear any responsibility, and you should always check original source before taking any actions